ViaDerma, Inc. has recently announced a series of new and noteworthy business developments that will undoubtedly pique the interest of current and potential stakeholders, customers, partners, and healthcare providers around the world, and especially in India.
The company finds itself in the conclusive stages of fulfilling stability testing requirements in collaboration with a third-party testing facility. Based on the recent feedback from their third-party testing partner, the company is on track to finalize all the necessary procedures by the end of October.
These stability testing requirements constitute a pivotal milestone towards obtaining approvals to distribute their flagship product, Vitastem Ultra, across multiple nations in the Caribbean, Middle East, and notably, India – now, the most populated nation in the world.
The dedicated management team at ViaDerma has been working tirelessly with their new contract manufacturer to bolster production capabilities, with the intent of accommodating substantial volume orders ranging from 250,000 to 300,000 units per country throughout the year.
Dr. Christopher Otiko, the Founder & CEO of ViaDerma, is expected to embark on a trip to Egypt in the fourth quarter to introduce Vitastem Ultra to government officials. This mission anticipates fulfilling purchase orders exceeding 250,000 units in Egypt alone.
Once the stability testing phase for Vitastem Ultra concludes, the company will embark on its international distribution journey, catering to the robust demand for Vitastem in India, along with the Caribbean, Middle East, and Egypt. Discussions with their sales partners suggest an initial distribution of over 300,000 units per country annually, with plans to progressively augment the volume across these regions.
A pivotal addition to the company’s arsenal is their new, larger product manufacturer situated in the United States. This manufacturing capacity is integral to fulfilling the escalating demand for innovative topical antibiotics like Vitastem Ultra.
These antibiotics are crucial in combating the growing prevalence of superbugs, such as staph and MRSA, which often result from healthcare-associated infections (HAIs) worldwide. As these infections pose significant health risks to patients, medical personnel, and their families, Vitastem stands as a proven solution to this grave concern.
According to Dr. Otiko, “2023 is shaping up to be a very pivotal year for ViaDerma, and we are extremely excited about the future of our business moving forward. The growing demand for Vitastem is testament to the powerful healing properties this broad-spectrum topical antibiotic offers to healthcare globally.
Our team is working around the clock to ensure operations, manufacturing, and product distribution are sound and ready to meet this growing demand around the world and fulfill purchase orders in the hundreds of thousands per country with the expectations to continually compound sales growth throughout 2024 and beyond.”
Their management team at ViaDerma expresses their deep gratitude for the unwavering support, patience, and feedback from their stakeholders, partners, customers, and healthcare providers. They are thrilled about the progress made this year and the bright future of their business over the next year. The company eagerly anticipates sharing further updates as they develop.
Who is ViaDerma?
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company dedicated to introducing new products to the market and licensing their innovative transdermal drug delivery technology solutions to established leaders in the pharmaceutical industry across a wide range of therapeutic areas.
What is Vitastem Ultra?
Vitastem Ultra is an FDA-registered topical antibiotic spray and one of the strongest first aid & wound care treatments for infection prevention available for over the counter (OTC) use in the world. Vitastem is a multi-use topical antibiotic that is safe for all age groups and is best used for treating acne, burns, cuts & scrapes, diabetic ulcers, eczema, psoriasis, lacerations, scars, shingles, staph, MRSA, and other minor to severe wounds like no other antibiotic available to consumers in the market.
| Are you an
Entrepreneur or Startup? Do you have a Success Story to Share? SugerMint would like to share your success story. We cover entrepreneur Stories, Startup News, Women entrepreneur stories, and Startup stories
|
Read more business articles related to Sales, Marketing, Advertising, Finance, Entrepreneurship, Management, Education, and Industry at SugerMint.